$Recursion Pharmaceuticals, In

Source: Recursion Pharmaceuticals, Inc

The combined company’s therapeutic partnerships represent more than 10 partnered programs in areas such as oncology and immunology.

The combined company has received approximately $450M in upfront and milestone payments from partnerships to date.

Through these partnerships, the company has the potential to receive more than approximately $20B in additional milestone payments before royalties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":387815963156568,"tweetId":"387815963156568","gmtCreate":1735712156110,"gmtModify":1735715682085,"author":{"id":3576143479038940,"idStr":"3576143479038940","authorId":3576143479038940,"authorIdStr":"3576143479038940","name":"Mike Yong","avatar":"https://community-static.tradeup.com/news/af67eb1674939c91d407718f5b29ebea","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","exceedPercentage":"93.53%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":12,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/36170c9a5ab7919de3512b334a683ee0","width":"1290","height":"706"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/36170c9a5ab7919de3512b334a683ee0","width":"1290","height":"706"}],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/RXRX\">$Recursion Pharmaceuticals, Inc.(RXRX)$&nbsp;</a>&nbsp;\n \n\nSource: Recursion Pharmaceuticals, Inc\nThe combined company’s therapeutic partnerships represent more than 10 partnered programs in areas such as oncology and immunology.\nThe combined company has received approximately $450M in upfront and milestone payments from partnerships to date.\nThrough these partnerships, the company has the potential to receive more than approximately $20B in additional milestone payments before royalties.\n <img src=\"https://community-static.tradeup.com/news/36170c9a5ab7919de3512b334a683ee0\" tg-width=\"1290\" tg-height=\"706\"></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/RXRX\">$Recursion Pharmaceuticals, Inc.(RXRX)$&nbsp;</a>&nbsp;\n \n\nSource: Recursion Pharmaceuticals, Inc\nThe combined company’s therapeutic partnerships represent more than 10 partnered programs in areas such as oncology and immunology.\nThe combined company has received approximately $450M in upfront and milestone payments from partnerships to date.\nThrough these partnerships, the company has the potential to receive more than approximately $20B in additional milestone payments before royalties.\n <img src=\"https://community-static.tradeup.com/news/36170c9a5ab7919de3512b334a683ee0\" tg-width=\"1290\" tg-height=\"706\"></body></html>","text":"$Recursion Pharmaceuticals, Inc.(RXRX)$ Source: Recursion Pharmaceuticals, Inc The combined company’s therapeutic partnerships represent more than 10 partnered programs in areas such as oncology and immunology. The combined company has received approximately $450M in upfront and milestone payments from partnerships to date. Through these partnerships, the company has the potential to receive more than approximately $20B in additional milestone payments before royalties.","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/387815963156568","repostId":0,"isVote":1,"tweetType":1,"viewCount":690,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["RXRX"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":414,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/387815963156568"}